Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: J Thorac Oncol. 2023 May 18;18(9):1222–1232. doi: 10.1016/j.jtho.2023.05.008

Figure 3. Overall survival estimates by CD8+ T cell infiltration and MHC-I expression.

Figure 3.

A. Kaplan-Meier curves of overall survival based on presence or absence of at least 1% of cells within the tumor expressing CD8 by immunohistochemistry, for patients treated with nivolumab (left) or nivolumab and ipilimumab (right). A. Kaplan-Meier curves of overall survival based on presence or absence of at least 30% of cells within the tumor expressing MHC-I by immunohistochemistry, for patients treated with nivolumab (left) or nivolumab and ipilimumab (right).